Abstract 21P
Background
Due to the limited accessibility of trastuzumab, the majority of Her2 positive breast cancer patients are treated mainly with systemic chemotherapy in Myanmar. This study aimed to find out the clinical outcome of treatment without trastuzumab for Her2 positive breast cancer patients.
Methods
A retrospective observational study of total 156 Her2 positive breast cancer patients not receiving anti-her2 therapy who diagnosed between January 2007 and December 2016 in two private oncology centers in Yangon, Myanmar.
Results
In this study, median age of patients was 52 years (25yrs-87yrs). Majority (80%, n = 126) were in early stage. Regarding treatment pattern, 99% of patients underwent either simple or total mastectomy and only 1% was done breast conserving surgery. Anthracycline containing regimes (AC-T or FAC) were given in 99% of patients. Among them, 26% (n = 40) took additional maintenance chemotherapy with oral cyclophosphamide and methotrexate for 3 to 6 months after conventional chemotherapy. After a median follow up of 40 months (8-120), 80% of patients achieved complete response. The median disease free period was 34 months and 3 year invasive disease free survival was 79%. The relapse rate was 17.3%. Lymph nodes (23%) and liver metastases (23%) were the first site of recurrence in relapsed patients. Furthermore, 92% had no recurrence among those received maintenance chemotherapy.
Conclusions
Anthracycline based systemic chemotherapy without anti Her2 therapy showed good clinical outcome in Her2 positive breast cancer patients in real clinical practice in Myanmar.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Medical oncology academic group.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
437P - Correlation between bio-impedance analysis and abdominal CT scan to diagnose decreased muscle mass in adult cancer patients
Presenter: Andree Kurniawan
Session: Poster display session
Resources:
Abstract
438P - Evaluating mitochondrial biomarkers between fatigue subclasses identified using latent class analysis in early-stage breast cancer patients
Presenter: Yi Long Toh
Session: Poster display session
Resources:
Abstract
440P - Accuracy of risk scoring system to determine delayed chemotherapy induced nausea and vomiting (CINV) in cancer patients
Presenter: Jada Harika
Session: Poster display session
Resources:
Abstract
441P - A pilot cross-sectional study on incidence of liver toxicity in cancer patients on western anti-cancer drug therapy with or without concurrent Chinese herbal medicine
Presenter: Tsz Him So
Session: Poster display session
Resources:
Abstract
442P - Relationship between QOL and support elderly patients with permanent colostomies
Presenter: Yukiko Orii
Session: Poster display session
Resources:
Abstract
443P - The effectiveness of individual nutritional counselling for patients with advanced cancer undergoing chemotherapy: A preliminary study
Presenter: Saori Koshimoto
Session: Poster display session
Resources:
Abstract
444P - The prophylactic effect of 0.1% fluorometholone eye drops on eye disorders caused by high-dose cytarabine
Presenter: Takayuki Tsuchiya
Session: Poster display session
Resources:
Abstract
445P - Safety and feasibility of extending flushing interval every 3 months for maintenance of TICVPS in CRC patients after completion of curative intended treatments
Presenter: Sang Bo Oh
Session: Poster display session
Resources:
Abstract
446P - Accuracy of risk scoring system to determine chemotherapy induced nausea and vomiting (CINV) in cancer patients receiving first cycle chemotherapy
Presenter: Jada Harika
Session: Poster display session
Resources:
Abstract
447P - Hypomagnesaemia: An unnoticed problem in lung cancer patients treated with concurrent chemoradiation
Presenter: Sharif Ahmed
Session: Poster display session
Resources:
Abstract